Literature DB >> 17855362

APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription.

Xiao-Yu Li1, Fei Guo, Li Zhang, Lawrence Kleiman, Shan Cen.   

Abstract

Human APOBEC3G (hA3G) has been identified as an anti-HIV-1 host factor. The presence of hA3G in HIV-1 strongly inhibits the ability of the virus to produce new viral DNA upon infection. In this report, we demonstrate that the reduction of late viral DNA synthesis is due to the inhibition by hA3G of the strand transfer steps that occur during reverse transcription. Analysis of viral cDNA intermediates in vivo reveals that hA3G causes an inhibition of the minus and plus strand transfers, without having a significant impact on DNA elongation. Using an in vitro system to measure minus strand transfer similarly shows a dose-dependent reduction of strand transfer by hA3G. This inhibition of strand transfer occurs independently the editing activity of hA3G and is correlated with its ability to prevent RNaseH degradation of the template RNA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17855362     DOI: 10.1074/jbc.M703423200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  99 in total

Review 1.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

2.  APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.

Authors:  Holly A Sadler; Mark D Stenglein; Reuben S Harris; Louis M Mansky
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

Review 3.  Role of HIV-1 nucleocapsid protein in HIV-1 reverse transcription.

Authors:  Judith G Levin; Mithun Mitra; Anjali Mascarenhas; Karin Musier-Forsyth
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

4.  The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication.

Authors:  Xiaoxia Wang; Zhujun Ao; Liyu Chen; Gary Kobinger; Jinyu Peng; Xiaojian Yao
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

Review 5.  Advances in the structural understanding of Vif proteins.

Authors:  Pierre Barraud; Jean-Christophe Paillart; Roland Marquet; Carine Tisné
Journal:  Curr HIV Res       Date:  2008-03       Impact factor: 1.581

Review 6.  Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.

Authors:  Belete A Desimmie; Krista A Delviks-Frankenberrry; Ryan C Burdick; DongFei Qi; Taisuke Izumi; Vinay K Pathak
Journal:  J Mol Biol       Date:  2013-11-02       Impact factor: 5.469

7.  Recombinant rabbit single-chain antibodies bind to the catalytic and C-terminal domains of HIV-1 integrase protein and strongly inhibit HIV-1 replication.

Authors:  Frederico Aires da Silva; Min Li; Sylvie Rato; Sara Maia; Rui Malhó; Kylie Warren; David Harrich; Robert Craigie; Carlos Barbas; Joao Goncalves
Journal:  Biotechnol Appl Biochem       Date:  2012-10-10       Impact factor: 2.431

8.  Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences.

Authors:  Andrew E Armitage; Aris Katzourakis; Tulio de Oliveira; John J Welch; Robert Belshaw; Kate N Bishop; Beatrice Kramer; Andrew J McMichael; Andrew Rambaut; Astrid K N Iversen
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

9.  Insulin-like growth factor II mRNA binding protein 1 associates with Gag protein of human immunodeficiency virus type 1, and its overexpression affects virus assembly.

Authors:  Yongdong Zhou; Liwei Rong; Jennifer Lu; Qinghua Pan; Chen Liang
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

10.  Exosomes packaging APOBEC3G confer human immunodeficiency virus resistance to recipient cells.

Authors:  Atanu K Khatua; Harry E Taylor; James E K Hildreth; Waldemar Popik
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.